Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Open access
Pott, Christiane, Hoster, Eva, Delfau-Larue, Marie-Helene, Beldjord, Kheira, Böttcher, Sebastian, Asnafi, Vahid, Plonquet, Anne, Siebert, Reiner, Callet-Bauchu, Evelyne, Andersen, Niels, van Dongen, Jacques J. M., Klapper, Wolfram, Berger, Françoise, Ribrag, Vincent, van Hoof, Achiel L., Trneny, Marek, Walewski, Jan, Dreger, Peter, Unterhalt, Michael, Hiddemann, Wolfgang, Kneba, Michael, Kluin-Nelemans, Hanneke C., Hermine, Olivier, Macintyre, Elizabeth, Dreyling, Martin·2010·Blood

Abstract

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-06-230250

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 272

Metadata

Authors
Pott, C., Hoster, E., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet-Bauchu, E., Andersen, N., van Dongen, J. J. M., Klapper, W., Berger, F., Ribrag, V., van Hoof, A. L., Trneny, M., Walewski, J., Dreger, P., Unterhalt, M., Hiddemann, W., Kneba, M., Kluin-Nelemans, H. C., Hermine, O., Macintyre, E., & Dreyling, M.
Venue
Blood
Published
2010-04-22
Volume
115
Issue
16
Pages
3215-3223
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2065464657
Cited by
272
References
22
FWCI
10.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. https://app.cochat.ai/papers/10.1182/blood-2009-06-230250
The paper
Pott, C., Hoster, E., Delfau-Larue, M.-H., Beldjord, K., Böttcher, S., Asnafi, V., Plonquet, A., Siebert, R., Callet-Bauchu, E., Andersen, N., van Dongen, J. J. M., Klapper, W., Berger, F., Ribrag, V., van Hoof, A. L., Trneny, M., Walewski, J., Dreger, P., Unterhalt, M., . . . Dreyling, M. (2010). Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. https://doi.org/10.1182/blood-2009-06-230250

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.